Rapid Selection of HIV-2 Capsid Mutations in Salvage Therapy with Lenacapavir-Containing Regimen

IF 8.2 1区医学 Q1 IMMUNOLOGY

Clinical Infectious Diseases Pub Date : 2024-12-30 DOI:10.1093/cid/ciae650

Thomas Montrouge, Mélanie Bertine, Gilles Peytavin, Thibault Saint Joannis, Antoine Bachelard, Pierre De Truchis, Sylvie Lariven, Philippe Morlat, Cécile Pouderoux, Florence Damond, Naomi Sayre, Roland Tubiana, Nadia Valin, Charlotte Charpentier, Diane Descamps, Jade Ghosn, Quentin Le Hingrat

引用次数: 0

Abstract

Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with multi-drug resistant HIV-2 viruses, virological suppression was not achieved after a year and most patients selected capsid drug-resistance associated mutations.

查看原文本刊更多论文

在含有lenacapvir的挽救治疗方案中快速选择HIV-2衣壳突变

Lenacapavir是首个衣壳抑制剂，目前已被批准用于多药耐药HIV-1感染。我们报道，尽管含有lens的方案对多重耐药HIV-2病毒患者有初步疗效，但一年后没有达到病毒学抑制，大多数患者选择了衣壳耐药相关突变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Infectious Diseases 医学-传染病学

CiteScore

25.00

自引率

2.50%

发文量

900

审稿时长

3 months

期刊介绍： Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.